Josh Arnold Investment Consultant LLC Buys New Shares in The Oncology Institute, Inc. $TOI

Key Points

• Josh Arnold Investment Consultant LLC has acquired a new position in The Oncology Institute, Inc. ($TOI), purchasing approximately 1,988,900 shares valued at $2.27 million.
• A number of other institutional investors, including Citizens Financial Group and WealthShield Partners, have also initiated new stakes in Oncology Institute, reflecting increased interest in the stock.
• Analyst ratings for $TOI remain favorable, with a consensus rating of "Buy" and an average price target of $7.00, as per recent research reports.

Josh Arnold Investment Consultant LLC purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,988,900 shares of the company's stock, valued at approximately $2,267,000. Oncology Institute comprises about 1.9% of Josh Arnold Investment Consultant LLC's holdings, making the stock its 7th largest holding. Josh Arnold Investment Consultant LLC owned 2.63% of Oncology Institute at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Jane Street Group LLC increased its stake in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after purchasing an additional 109,769 shares in the last quarter. WealthShield Partners LLC bought a new stake in Oncology Institute in the first quarter valued at approximately $80,000. Citizens Financial Group Inc. RI bought a new stake in Oncology Institute in the first quarter valued at approximately $71,000. XTX Topco Ltd increased its stake in Oncology Institute by 49.5% in the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock valued at $63,000 after purchasing an additional 18,448 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares in the last quarter. 36.86% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Oncology Institute news, Director Growth I. L.P. M33 sold 6,018,168 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the transaction, the director directly owned 7,932,389 shares of the company's stock, valued at $24,511,082.01. This trade represents a 43.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.50% of the company's stock.

Oncology Institute Stock Performance

Shares of NASDAQ TOI traded down $0.04 during mid-day trading on Wednesday, reaching $3.20. 727,466 shares of the company were exchanged, compared to its average volume of 1,477,710. The company's 50-day simple moving average is $3.47 and its 200-day simple moving average is $2.53. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 14.58. The stock has a market capitalization of $298.73 million, a P/E ratio of -4.71 and a beta of 0.10. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $4.50.

Wall Street Analysts Forecast Growth

TOI has been the subject of several research reports. Noble Financial initiated coverage on shares of Oncology Institute in a research report on Wednesday, July 23rd. They set an "outperform" rating and a $8.00 price objective for the company. BTIG Research initiated coverage on shares of Oncology Institute in a report on Thursday, May 15th. They set a "buy" rating and a $7.00 target price for the company. Finally, B. Riley initiated coverage on shares of Oncology Institute in a report on Wednesday, July 16th. They set a "buy" rating and a $6.00 target price for the company. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.